SCHEMBL22845214

SCHEMBL22845214

CC(C)NC(=O)c1cnn2c3c(c(=O)n(-c4ccccc4)c12)CCN(C(=O)c1ccc(Cl)c(Cl)c1)C3

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.37
MAPT P10636 5/20 0.37
ALDH1A1 P00352 2/20 0.37
GAA P10253 1/20 0.37
P2RX7 Q99572 2/20 0.36
TACR3 P29371 1/20 0.36
CCR1 P32246 1/20 0.36
HTT P42858 2/20 0.36
MTHFD2 P13995 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.35
HPGD P15428 1/20 0.35
POLB P06746 1/20 0.35
DYRK1A Q13627 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
MAPK14 Q16539 1/20 0.35
PGR P06401 1/20 0.35
PIK3CD O00329 1/20 0.34
PIK3R1 P27986 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22845293 0.90 HPGD (0.40) LMNAMAPTALDH1A1GAAP2RX7
SCHEMBL22845213 0.89 MTHFD2 (0.43) LMNAMAPTALDH1A1GAAP2RX7
SCHEMBL22845202 0.87 LMNA (0.40) LMNAMAPTALDH1A1GAATACR3
SCHEMBL22845409 0.86 TSHR (0.40) LMNAMAPTALDH1A1GAAP2RX7
SCHEMBL22845287 0.85 LMNA (0.37) LMNAMAPTALDH1A1GAAP2RX7
SCHEMBL22845327 0.84 TACR3 (0.40) LMNAMAPTALDH1A1GAAP2RX7
SCHEMBL24173921 0.84 DHODH (0.42) LMNAMAPTALDH1A1POLBMEN1
SCHEMBL22845328 0.83 ALDH1A1 (0.40) LMNAMAPTALDH1A1GAAP2RX7
SCHEMBL22845368 0.81 PREP (0.40) LMNAMAPTALDH1A1GAAHTT
SCHEMBL22845286 0.81 LMNA (0.40) LMNAMAPTALDH1A1GAAP2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220000874-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2022-01-06 US disclosed
US-11136321-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2021-10-05 US disclosed
US-20200407361-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2020-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220000874-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL LMNA 1680/4885MAPT 651/4885ALDH1A1 648/4885
US-11136321-B2 Tricyclic compounds SLC10A1, PKD1, CEL LMNA 1680/4885MAPT 651/4885ALDH1A1 648/4885
US-20200407361-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL LMNA 1680/4885MAPT 651/4885ALDH1A1 648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.